You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The approval was based on data showing superior efficacy for Alunbrig compared to Pfizer's Xalkori, especially in patients with brain metastasis.
Cerevance, a drug discovery firm employing the transcriptome sequencing method, raised $45 million in Series B financing earlier this month.
The international firm is one of several pharmaceutical companies emphasizing new single-cell technologies to improve existing drugs and find new ones.
GenAhead said it will use the IP it had licensed from ERS for genome editing applications in pharmaceutical drug discovery and development.
The company announced agreements to use the Oncomine Dx Target Test in drug development programs with Daiichi Sankyo, Takeda, and Spectrum Pharmaceuticals.
Takeda will use Definiens' new cloud-based digital pathology platform to conduct analyses for its clinical biomarkers development programs.
HudsonAlpha researchers are expected to sequence 20,000 patient tumor and non-tumor samples for ORIEN's Avatar initiative by 2019.
The partners will develop a biomarker discovery platform based on Exosome Diagnostics' exosomal RNA sequencing technology.
The Avatar Research Program will collect de-identified genomic and clinical information from consenting patients treated at ORIEN cancer centers.
The partners will screen for molecules that could revive metabolic activity in heart tissue damaged by cardiovascular disease or failure.
The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.
Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.
A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.
In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.